Archive for August, 2018
Antares: Investment Story has Shifted from Pipeline Promise to Commercial Potential (ATRS, $3.74, Buy)
Investment Summary At long last, the exciting new product potential of Antares is becoming a commercial reality. A very significant milestone for Antares was the approval gained by its distribution partner Teva in 2Q, 2016 for an AB rated generic to Imitrex (sumatriptan). This was the first of four AB rated generics that are known […]
AMAG Pharmaceuticals: Trying to Project 2019 Sales for the Makena Franchise (AMAG, $24.45, Buy)
Investment Thesis The investment outlook for AMAG in 2019 is primarily about Makena and this report focuses almost entirely on how much of the franchise can be maintained by the new auto-injector dosage form in the face of generic competition to the older intramuscular formulations. The Wall Street consensus 2019 sales estimate of around $200 […]
Cryoport: Reiterating My Buy Recommendation (CYRX, Buy, $14.20)
Investment Perspective On May 16, 2018, I published a report entitled Updated Sales and Earnings Model. The purpose of that report was to build a detailed sales model for the Company that for the first time incorporated Cryoport revenues arising from the sale of commercial products-the CAR-T drugs Kymriah and Yescarta. You may want to […]
Cytokinetics: Update based on 2Q, 2018 Conference Call (CYTK, Buy, $6.85)
Investment Thesis Omecamtiv is the Essence of the Investment Thesis I continue to believe that Cytokinetics is an attractive investment based on the potential for omecamtiv mecarbil, which promises to bring an important new mechanism of action to the treatment of congestive heart failure. If the ongoing phase 3, GALACIC-HF trial (a massive 8,000 patient […]